Continuous renal replacement therapy (CRRT) is a method used to assist patients recovering from acute renal failure. It aids them by eliminating excess volume of plasma water from their bodies. According to the National Center for Biotechnology Information (NCBI), nearly 200 million were afflicted with chronic kidney disease in 2014. CRRT can prevent the proliferation of the disease by removing toxins in 24 hours.
Types of CRRT include continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemofiltration (CVVH), and slow continuous ultra filtration (SCUF). Advantages include elimination of uremic toxins and correction of acid base anomalies.
Relieving Agent of Inflammatory Mediators
Different modalities of CRRT are CVVHD, CVVH, CVVHDF, and SCUF. Among these, the CVVHDF segment is projected to grow robustly from 2014 to 2025 due to high incidence of fluid overload cases. Benefits of convection and diffusion to remove solutes and fluids from the bloodstream are projected to augur segment growth. Developments in CRRT machines have the capacity to remove fluids more efficiently. For instance, the Spectral Apheresis Machine ("SAM") gained approval in 2017 from the U.S. Food and Drug Administration (FDA) for treating sepsis and plasma exchange.
The CVVH segment had dominated the CRRT market in 2016 due to fluid overload being a constant symptom in acute kidney injury cases. According to an article published in Elsevier in 2009, congestive heart failure can be a major cause of death in dialysis patients. The use of CVVH in reducing the mortality rate can drive segment demand from 2014 to 2025. In a case study for a liver transplant, CVVH coupled with CytoSorb, an adsorber, managed to successfully relieve the patient of any inflammatory cytokines and improved blood levels.
Market Overview
The continuous renal replacement therapy (CRRT) market is touted to touch USD 1.4 billion by 2025, according to a report by Grand View Research, Inc. Presence of various chronic diseases such as acute renal failure, diabetes, and kidney diseases are predicted to drive market growth over the forecast period (2014-2025).
Rise in geriatric populace, expendable income of patients, and technological advances in CRRT is expected to spur market growth. Lack of trained nurses and high costs of CRRT may hamper market growth. Key market players include Asahi Kasei Corporation, B. Braun Melsungen AG, Fresenius Medical Care AG & Co. KGaA, and Medtronic plc.
In-Depth Research Report On Continuous Renal Replacement Therapy (CRRT) Market:
https://www.grandviewresearch.com/industry-analysis/continuous-renal-replacement-therapy-crrt-market
No comments:
Post a Comment